Stefano Monti PhD

Associate Professor, Computational Biomedicine

Associate Professor, Biostatistics

75 E. Newton St | (617) 414-7031
smonti@bu.edu

Sections

Computational Biomedicine

Centers

BU-BMC Cancer Center

Evans Center for Interdisciplinary Biomedical Research

Biography

Stefano Monti is a Computational Biologist and joined the BU faculty in January 2011 in the section of Computational Biomedicine, with joint appointments in the Biostatistics Department and the Bioinformatics program. Monti received his Ph.D. in Intelligent Systems and Artificial Intelligence from the University of Pittsburgh, and completed his training with a post-doctoral fellowship at the Robotics Institute at Carnegie Mellon. His doctoral and post-doctoral research focused on the development of machine learning and knowledge discovery methodologies, with a particular emphasis on probabilistic reasoning and Bayesian approaches to modeling biomedical data. Since 2001, he has worked in the field of Cancer Genomics, first as a Research Scientist at the Whitehead Institute’s Center for Genome Research, and later as a Computational Biologist in the Cancer Program at the Broad Institute.

Dr. Monti's laboratory integrates systems biology, machine learning, and bioinformatics approaches to investigate the molecular drivers of human disease, with the goals of advancing prevention and care. This multidisciplinary effort relies on the development of novel computational methodologies, and on the design of experiments based on the generation and integrative analysis of high-throughput multi-omics data, with the goal of identifying novel therapeutic targets and developing accurate diagnostic and prognostic biomarkers. Specific areas of research include the study of the molecular mechanisms of tumor initiation and progression and of the role played in it by environmental exposure, as well as the study of the biological factors contributing to healthy aging and extreme longevity.

Other Positions

Websites

BU Profile

Department of Medicine Faculty

Twitter

Researchgate

Education

Artificial Intelligence, PhD, University of Pittsburgh, 1999

Artificial Intelligence, MS, University of Pittsburgh, 1995

Computer Science, MS, University of Houston, 1993

Computer Science, BS, Università degli Studi di Udine, 1991

Publications

Published on 3/31/2023

Karagiannis TT, Dowrey TW, Villacorta-Martin C, Montano M, Reed E, Belkina AC, Andersen SL, Perls TT, Monti S, Murphy GJ, Sebastiani P. Multi-modal profiling of peripheral blood cells across the human lifespan reveals distinct immune cell signatures of aging and longevity. EBioMedicine. 2023 Apr; 90:104514. PMID: 37005201.

PubMed

Published on 3/29/2023

Leshchyk A, Xiang Q, Andersen SL, Gurinovich A, Song Z, Lee JH, Christensen K, Yashin A, Wojczynski M, Schwander K, Perls TT, Monti S, Sebastiani P. Mosaic chromosomal alterations and human longevity. J Gerontol A Biol Sci Med Sci. 2023 Mar 29. PMID: 36988570.

PubMed

Published on 3/29/2023

PubMed

Published on 3/24/2023

Khan MM, Frustino J, Villa A, Nguyen BC, Woo SB, Johnson WE, Varelas X, Kukuruzinska M, Monti S. Total RNA sequencing reveals gene expression and microbial alterations shared by oral pre-malignant lesions and cancer. bioRxiv. 2023 Mar 24. PMID: 36993637.

PubMed

Published on 1/19/2023

Karagiannis TT, Monti S, Sebastiani P. Bayesian Differential Analysis of Cell Type Proportions. bioRxiv. 2023 Jan 19. PMID: 36712131.

PubMed

Published on 11/28/2022

Kern JG, Tilston-Lunel AM, Federico A, Ning B, Mueller A, Peppler GB, Stampouloglou E, Cheng N, Johnson RL, Lenburg ME, Beane JE, Monti S, Varelas X. Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas. Nat Commun. 2022 Nov 28; 13(1):7198. PMID: 36443313.

PubMed

Published on 11/4/2022

Jafari N, Chen A, Kolla M, Pompa IR, Qiu Y, Yu R, Llevenes P, Ennis CS, Mori J, Mahdaviani K, Halpin M, Gignac GA, Heaphy CM, Monti S, Denis GV. Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease. Adv Cancer Biol Metastasis. 2022 Dec; 6. PMID: 36644690.

PubMed

Published on 8/23/2022

Sebastiani P, Song Z, Ellis D, Tian Q, Schwaiger-Haber M, Stancliffe E, Lustgarten MS, Funk CC, Baloni P, Yao CH, Joshi S, Marron MM, Gurinovich A, Li M, Leshchyk A, Xiang Q, Andersen SL, Feitosa MF, Ukraintseva S, Soerensen M, Fiehn O, Ordovas JM, Haigis M, Monti S, Barzilai N, Milman S, Ferrucci L, Rappaport N, Patti GJ, Perls TT. A metabolomic signature of the APOE2 allele. Geroscience. 2023 Feb; 45(1):415-426. PMID: 35997888.

PubMed

Published on 8/1/2022

Shah HS, Moreno LO, Morieri ML, Tang Y, Mendonca C, Jobe JM, Thacker JB, Mitri J, Monti S, Niewczas MA, Pennathur S, Doria A. Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies. Diabetes Care. 2022 Aug 01; 45(8):1882-1892. PMID: 35696261.

PubMed

Published on 5/4/2022

Alhousami T, Diny M, Ali F, Shin J, Kumar G, Kumar V, Campbell JD, Noonan V, Hanna GJ, Denis GV, Monti S, Kukuruzinska MA, Varelas X, Bais MV. Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition. Mol Cancer Res. 2022 May 04; 20(5):712-721. PMID: 35105672.

PubMed

View full list of 129 publications.